About us > Strategy
Acacia Pharma is a pharmaceutical company focused on cancer supportive care, utilising a product discovery & development model that generates product opportunities with a higher probability of success, based on established drugs. Management believes Acacia is uniquely positioned to create a successful company within an area of substantial growth, using its cash efficient, rapid proof-of-principle, business model.
Cancer supportive care is the management of the symptoms of cancer, or the management of side-effects of the treatments of cancer. Oncologists have recognised the need to treat patients with supportive care therapies to allow them to either receive the optimum drug required, or dose of drug, to treat their cancer and to increase their quality of life. This recent change of perspective reflects a) the increasingly chronic nature of cancer therapy due to new, more effective anticancer therapies, b) increasing demands from patients and their carers for improved quality, as well as quantity, of life, and c) the increasing use of some of the new anti-cancer agents which have specific side effect profiles and therefore represent a new challenge to physicians.
Acacia discovers and develops cancer supportive care product opportunities based on established drugs which therefore have a higher probability of success. These product opportunities comprise new uses for existing drugs, optimised drug delivery presentations or optimised enantiomer products. This approach allows Acacia to capitalise on publicly available information, thereby lowering development risk, time and cost compared to new chemical or molecular entities, whilst delivering products of high value in areas of high unmet need.
Acacia has established a commercially-led drug discovery & development process. It prioritises its discovery & development activities by assessing the results of market research, the Company’s ability to identify a product that meets the target product profile needed by physicians, and the product’s perceived development path. Acacia then seeks an established drug having the pharmacological target profile it has defined. Products are protected through patents covering the new use and/or the optimal delivery system and enantiomer profile.
Acacia operates a virtual business model and has an experienced management team, members of which have successfully conceived, managed and exited similar businesses. The team has extensive expertise in all areas considered core to the business and is complemented by a network of industry consultants.